P129
P3781
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusP4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profileSingle-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.Protease inhibitors: silver bullets for chronic hepatitis C infection?Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV).Boceprevir: a protease inhibitor for the treatment of hepatitis C.Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infectionLack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.Characterization of resistance mutations against HCV ketoamide protease inhibitors.Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver TransplantationBoceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)Boceprevir-induced Herpes ZosterBoceprevirBoceprevir
P921
Q26830190-0B9EC640-4820-4DC2-A04A-174B834DCB1EQ27658593-416B7175-1174-4CBE-88AB-A512B1FFC65DQ33455220-C40D8D17-D7D6-4E1E-88BA-635658FB82E1Q34206923-0DAD1FD3-B1FF-428D-AD45-955F8842D952Q37968485-9E54E90C-5B01-4B31-8D41-E50364F6E55EQ37989914-382A3F7B-AFFD-42B4-A997-C6FDDEE82F3BQ37990840-2434C500-4943-4A50-875F-BFFE1F413CBAQ37991388-4AC396D6-3964-4738-A5E6-3763F1D8D5CEQ37992195-7384D542-1C62-4C22-B000-212C5B5F566DQ38002870-C0C34474-B5BC-414A-A341-428AB347F491Q38024470-95BD8A42-A08D-4AD7-90FA-883561D59C7DQ38043288-E8CCC303-098A-417D-850B-5B5940895E62Q38047026-472D0381-EF28-4169-9D9F-19C78A01FA10Q42145002-0177E57B-FF2D-4F1F-9C21-A06091CD4D0DQ42669311-1519B777-BADB-4881-813B-EE1C22479047Q42987836-9D86328C-82FA-4160-9EE4-2647C95D56E9Q43031532-D07B5B70-625F-446D-9B5E-5213850F84C0Q43042505-278A471C-F82B-4F4C-BEA1-6604086BB654Q43046741-FEF695A8-4521-4D1F-AD73-9A9F06875F34Q43047638-7257218F-81D6-45A1-9A86-A008394ADCA1Q45357722-F7AABC97-2CD3-45DA-B141-4D37F468CECAQ50553316-9E5AEBA8-4960-472F-B936-E9B03CECAADEQ50553873-74AB5412-7149-4743-8C56-940568DF4A33Q61955637-6E5218F8-71D5-4E52-B361-35DA68C2A52EQ61956825-00ED793A-0C0D-4982-80EF-1063922B3E1EQ61965920-0C8D8148-8009-4C7D-9F12-D2C089D9EE95Q63828899-AC05C73E-996B-409B-85CF-2BB3355074A1Q64233092-36CAF032-7CC2-4494-90FF-A2B43A6F5A4DQ83928894-F3E9EE88-C1FB-4801-94D4-6A1623BA9E43Q85193098-AFCB12EB-6BAD-4A20-8A01-EE021A0A778D
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Boceprevir
@de
Boceprevir
@es
Boceprevir
@it
Boceprevir
@nl
Boceprevir
@sh
Boceprevir
@sl
Boceprevir
@sr
Boceprevir
@vi
Bosepreviiri
@fi
boceprevir
@en
type
label
Boceprevir
@de
Boceprevir
@es
Boceprevir
@it
Boceprevir
@nl
Boceprevir
@sh
Boceprevir
@sl
Boceprevir
@sr
Boceprevir
@vi
Bosepreviiri
@fi
boceprevir
@en
altLabel
SCH 503034
@en
SCH-503034
@en
Victrelis
@de
prefLabel
Boceprevir
@de
Boceprevir
@es
Boceprevir
@it
Boceprevir
@nl
Boceprevir
@sh
Boceprevir
@sl
Boceprevir
@sr
Boceprevir
@vi
Bosepreviiri
@fi
boceprevir
@en